Martin Nitschke

Dr. Martin Nitschke

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
MZMalte Ziemann
Malte Ziemann
NHNicole Heßler
Nicole Heßler
IKInke R. König
Inke R. König
NLNils Lachmann
Nils Lachmann
ADAndrea Dick
Andrea Dick
RKReinhard Kelsch
Reinhard Kelsch
The assignment of human leucocyte antigens (HLAs) against which antibodies are detected as unacceptable antigens (UAGs) avoids allocation of HLA- incompatible allografts. There is uncertainty as to what extent UAGs decrease the probability of receiving a kidney offer. Kidney transplantations in 3264 patients on the waiting lists of six German transplant centres were evaluated for a period of at least 2 years. The proportion of excluded offers due to UAGs was calculated as virtual panel-reactive antibodies (vPRAs). In the common Eurotransplant Kidney Allocation Scheme, the transplant probability was unaffected by vPRAs in exploratory univariate analyses. In the multivariable model, a 1% increase in vPRA values was outweighed by an additional waiting time of 2.5 weeks. The model was confirmed using an external validation cohort of 1521 patients from seven centres. If only patients with standard risk were considered (e.g. no simultaneous transplantation of other organs), only 1.3 weeks additional waiting time was needed. In the Eurotransplant Senior Program, patients with vPRA values >50% had a strongly reduced transplant probability in the unadjusted analyses. In the multivariable model, a 1% increase in vPRA values was outweighed by an additional waiting time of 5 weeks. This study demonstrates that the assignment of UAGs decreases the transplant probability in both main Eurotransplant allocation programs because of insufficient compensatory mechanisms. At present, for immunized patients, a prolonged waiting time has to be weighed against the increased immunologic risk due to donor-specific antibodies not assigned as UAGs.

1 January 2017 in Transfusion Medicine Reviews
Verified
Journal Article
Closed access
JBJan Beneke
Jan Beneke
ASAleksej Sartison
Aleksej Sartison
JKJan T. Kielstein
Jan T. Kielstein
HHHermann Haller
Hermann Haller
MNMartin Nitschke
Martin Nitschke
JMJan Menne
Jan Menne

20 March 2012 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
MZMalte Ziemann
Malte Ziemann
CSConstanze Schönemann
Constanze Schönemann
CBChristina Bern
Christina Bern
NLNils Lachmann
Nils Lachmann
MNMartin Nitschke
Martin Nitschke
SGSiegfried Görg
Siegfried Görg

25 September 2023 in Rheumatology International
Verified
Journal Article
Open access
PDF file
NBNorbert Blank
Norbert Blank
IKIna Kötter
Ina Kötter
MSMarc Schmalzing
Marc Schmalzing
Jürgen RechJürgen Rech
Jürgen Rech
KKKaroline Krause
Karoline Krause
MKMartin Krusche
Martin Krusche
To investigate clinical symptoms and genetic variants in patients from the German anti-IL-1 registry for autoinflammatory orphan diseases (GARROD) between 2013 and 2022. Multicentre, retrospective analysis of demographic, clinical and genetic data of patients with autoinflammatory diseases (AID) who received anti-IL-1 targeted therapy. The cohort comprised 152 patients with familial Mediterranean fever (FMF; n = 71), cryopyrin-associated periodic syndromes (CAPS; n = 43), TNF-receptor associated periodic syndrome (TRAPS; n = 19), mevalonate kinase deficiency (MKD; n = 3) and unclassified AID (uAID; n = 16). Inflammatory attacks started in 61.2% of the patients before the age of 18 years. The delay between the first AID attack and anti-IL-1 therapy was 17.8 years. Monogenetic AIDs were diagnosed by clinical symptoms. Genetic analyses confirmed the diagnosis in 87.3% of patients with FMF, 65.2% with CAPS and 94.8% with TRAPS. Among this group, heterozygous MEFV variants and variants of unknown significance (VUS) were detected in 22.5% of patients with FMF, 51.2% with CAPS and 47.4% with TRAPS. Patients with VUS were older at disease onset which is consistent with a milder phenotype. Twenty-four patients had secondary AA amyloidosis (AA) at initiation of anti-IL-1 therapy. The mean age of these patients was 16.4 years at their first attack and 44.9 years at the time of AA diagnosis. Turkish-Armenian ancestry correlated with MEFV variants and higher FMF disease activity compared to German ancestry. Molecular genetic analyses should substantiate the clinical diagnosis of a monogenetic AID. Our data support the concept of variable penetrance of VUS which can be associated with late-onset AID.

8 August 2024 in Transplantation Direct
Verified
Journal Article
Open access
MZMalte Ziemann
Malte Ziemann
MLMonika Lindemann
Monika Lindemann
MHMichael Hallensleben
Michael Hallensleben
WAWolfgang Altermann
Wolfgang Altermann
KAKarina Althaus
Karina Althaus
MVMurielle Verboom
Murielle Verboom
Background.: Preformed donor-specific HLA antibodies (DSA) are a well-known risk factor in kidney transplantation. There is still considerable debate, however, about the optimal risk stratification among patients with preformed DSA. Additionally, data on the prognostic value of different crossmatch assays in DSA-positive patients are scarce. Methods.: DSA-positive living kidney transplant recipients were selected from a multicenter study examining 4233 consecutive renal transplants. An additional 7 patients from 2 further centers were included. Flow cytometric crossmatches (FXM), Luminex-based crossmatches, and virtual crossmatches based on C1q- and C3d-binding antibodies (C1qXM and C3dXM) were performed retrospectively using pretransplant sera and lymphocytes isolated from fresh samples. These samples were obtained from 44 donor and recipient pairs from 12 centers. Clinical outcome data and the control group without DSA were compiled from the previous study and were supplemented by data on 10-y death-censored graft survival (10yGS). Results.: Between 19% (C3dXM) and 46% (FXM) of crossmatches were positive. Crossmatch-positive patients showed high incidences of antibody-mediated rejection (AMR) within 6 mo (up to 60% in B-cell FXM+ patients). The incidence of AMR in crossmatch-negative patients ranged between 5% (FXM−) and 13% (C1qXM−). 10yGS was significantly impaired in patients with positive T-cell FXM and total FXM compared with both patients without DSA and those with DSA with negative FXM. Conclusions.: Especially FXM are useful for risk stratification, as the outcome of DSA-positive, FXM-negative patients is similar to that of DSA-negative patients, whereas FXM-positive patients have both more AMR and decreased 10yGS. Because of their lower sensitivity, the significance of Luminex-based crossmatches, C1qXM, and C3dXM would have to be examined in patients with stronger DSA.

4 December 2021 in Clinical Transplantation
Verified
Journal Article
Open access
PDF file
HKHristos Karakizlis
Hristos Karakizlis
MRMarieke van Rosmalen
Marieke van Rosmalen
PBPhilipp Boide
Philipp Boide
IAIngolf Askevold
Ingolf Askevold
SVSerge Vogelaar
Serge Vogelaar
RWRolf Weimer
Rolf Weimer
Background: The shortage of organs for transplantation remains a global problem. The retransplantation of a previously transplanted kidney might be a possibility to expand the pool of donors. We provide our experience with the successful reuse of transplanted kidneys in the Eurotransplant region.Methods: A query in the Eurotransplant database was performed between January 1, 1995 and December 31, 2015, to find kidney donors who themselves had previously received a kidney graft.Results: Nine out of a total of 68,554 allocated kidneys had previously been transplanted. Four of these kidneys were transplanted once again. The mean interval between the first transplant and retransplantation was 1689±1682 days (SD; range 55–5,333 days). At the time of the first transplantation the mean serum creatinine of the donors was 1.0 mg/dl (.6–1.3 mg/dl) and at the second transplantation 1.4 mg/dl (.8–1.5 mg/dl). The mean graft survival in the first recipient was 50 months (2–110 months) and in the second recipient 111 months (40–215 months).Conclusion: Transplantation of a previously transplanted kidney may successfully be performed with well‐preserved graft function and long‐term graft survival, even if the first transplantation was performed a long time ago. Such organs should be considered even for younger recipients in carefully selected cases.